|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 利司扑兰>> 市场分析报告 |
利司扑兰市场分析报告 |
|
2020 Spinal Muscular Atrophy (SMA) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs ... -SP), ND602, NT-1654, branaplam (LMI070), maresin 1, risdiplam, RAG-06, TEC-1, REC-0000716, REC ... Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019 Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H1 2019 SUMMARY According to the recently published report 'Survival Motor Neuron Protein - Pipeline Review, H1 2019'; Survival Motor Neuron Protein ( ... Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Spinal Muscular Atrophy (SMA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Muscular Atrophy (SMA) - Drugs in ... Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type 1, Type 2, Type 3, Type 4), By Treatment (Gene Therapy, Drug), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 ... and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the ... ., received marketing approval for Evrysdi (risdiplam) from the EMA for the ... , F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with ... Survival Motor Neuron Protein - Pipeline Review, H2 2019 Survival Motor Neuron Protein - Pipeline Review, H2 2019 SUMMARY Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Survival of motor neuron or survival motor neuron (SMN) is a protein encoded by the SMN1 and SMN2 genes. The ... Spinal Muscular Atrophy (SMA) Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type ... by three major therapies: Roche’s Evrysdi® (risdiplam), Novartis’s Zolgensma® (onasemnogene abeparvovec-xioi ... in expanding access. Type Analysis Risdiplam (Evrysdi, Roche) Risdiplam is the first and only ... Spinal Muscular Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... adoption of medications, including nusinersen and risdiplam, which increase the production of the ... Global Spinal Muscular Atrophy Market - 2025-2033 ... ) approved a label extension for Evrysdi (risdiplam) to include babies under two months ... ’s approval of a new tablet version of Evrysdi (risdiplam) from Genentech expanded treatment options ... RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective This report provides you with a landscape description and analysis of discovery and development of small ... Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or ... Motor Neuron Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major motor neuron disease markets reached a value of US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034. The motor neuron disease market ... Spinal Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major spinal disorders markets reached a value of US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.09% during 2024-2034. The spinal disorders market has been ... PTC Therapeutics Inc (PTCT) - Financial and Strategic SWOT Analysis Review ... . Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy; Translarna ... |